Fredag 27 December | 01:43:21 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-06 12:00 Kvartalsrapport 2025-Q3
2025-08-21 12:00 Kvartalsrapport 2025-Q2
2025-05-01 12:00 Kvartalsrapport 2025-Q1
2025-04-24 N/A Årsstämma
2025-03-20 N/A Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-02 - Kvartalsrapport 2024-Q1
2024-04-26 - X-dag ordinarie utdelning VIRO 0.00 DKK
2024-04-25 - Årsstämma
2024-03-21 - Bokslutskommuniké 2023
2023-11-24 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-05-04 - Kvartalsrapport 2023-Q1
2023-04-28 - X-dag ordinarie utdelning VIRO 0.00 DKK
2023-03-23 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-04 - Kvartalsrapport 2022-Q1
2022-04-29 - X-dag ordinarie utdelning VIRO 0.00 DKK
2022-04-28 - Årsstämma
2022-03-23 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-04-29 - Kvartalsrapport 2021-Q1
2021-04-28 - X-dag ordinarie utdelning VIRO 0.00 DKK
2021-04-27 - Årsstämma
2021-03-24 - Bokslutskommuniké 2020
2020-10-27 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-06-19 - X-dag ordinarie utdelning VIRO 0.00 DKK
2020-06-18 - Årsstämma
2020-04-30 - Kvartalsrapport 2020-Q1
2020-03-25 - Bokslutskommuniké 2019
2019-10-28 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-04-29 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning VIRO 0.00 DKK
2019-04-25 - Årsstämma

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriMedicinteknik
Virogates är verksamt inom medicinteknik. Idag innehas affärsverksamhet inom forskning och utveckling av biomarkörer och diagnostiska instrument för sjukvårdsindustrin. Produkterna säljs under olika varumärken och används vid identifiering, analys och vidarebehandling av sjukdomar, främst hjärt- och kärlsjukdomar, cancer och neurologiska sjukdomar. Bolaget etablerades 2001 och har sitt huvudkontor i Birkerød.
2024-11-11 17:05:00

Company Announcement no. 10/2024 (November 11, 2024)

BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical diagnostics company developing blood tests that can predict disease risk by measuring levels of stable chronic inflammation in individuals, announces that the capital raise of approximately DKK 8.2 million in relation to the directed emission to suPAR Remedy LLC has been completed. The issue of 1,289,510 new shares at a price of DKK 6.34 per share, resulting in a total subscription price of 8,179,224 DKK, has been registered with the Danish Business Authority. 

Prior to the increase, the Company’s share capital amounted to DKK 6,447,554, consisting of 6,447,554 shares of nominally DKK 1 each. After the nominal increase of DKK 1,289,510, the Company’s share capital now amounts to DKK 7,737,064, consisting of 7,737,064 shares of nominally DKK 1 each. 

The change in share capital is reflected in the Company’s articles of association available on the Company’s website. 

Further information regarding the directed emission to suPAR Remedy LLC can be found in Company Announcement no. 8 from October 14, 2024.

For further information, please contact: 
ViroGates A/S: 
CEO, Jakob Knudsen 
Tel. (+45) 2226 1355, email: jk@virogates.com 
 
Certified Advisor: 
Västra Hamnen Corporate Finance 
Per Lönn 
Tel. (+46) 40 200 250, email: ca@vhcorp.se 
 
About ViroGates 
ViroGates A/S is an international medical technology company developing blood tests for the measurement of chronic inflammation in health clinics and to improve patient care in hospitals. ViroGates markets its blood test products under the suPARnostic® brand. 
 
The company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com